JBSNF-000088

NNMT sits at the intersection of NAD-plus and methylation metabolism, and elevated NNMT activity has been associated with obesity, type 2 diabetes, and tumor progression. JBSNF-000088 was characterized as a slow-turnover substrate analogue that binds NNMT and, upon N-methylation, remains associated with the enzyme; co-crystal structures captured its methylated product bound in the active site ^[1].

In high-fat-diet-induced obese mice, JBSNF-000088 lowered 1-methylnicotinamide, reduced body weight, improved insulin sensitivity, and normalized glucose tolerance to lean-control levels, effects that were absent in NNMT-knockout mice, confirming on-target specificity ^[1]. Subsequent studies repurposed the compound as an NNMT probe in oncology, where NNMT inhibition reduced proliferation, migration, and invasion in models of gallbladder carcinoma, endometriosis-associated stromal cells, lung-cancer drug resistance, and ovarian cancer ^[2][3][4][1].

JBSNF-000088 is a preclinical research chemical with no human data and no CNS or nootropic indication. Its inclusion here corrects a common misattribution: it is an NNMT enzyme inhibitor arising from metabolic-disease drug discovery, not a monoaminergic or trace-amine compound.

JBSNF-000088 is an investigational, preclinical research compound supplied for laboratory use only (RUO); it is not approved for human use and is not a dietary supplement. It was reported to be effective and specific in rodent studies, but no controlled human safety data exist ^[1]. Because NNMT participates in core metabolic and methylation pathways, systemic effects of chronic inhibition in humans are unknown. Self-administration is not advised.

JBSNF-000088 was described in a 2018 collaboration between Sanofi and Jubilant Biosys as a small-molecule NNMT inhibitor for metabolic disorders, characterized structurally and pharmacologically in animal models of obesity and type 2 diabetes ^[1]. It was subsequently adopted as a reference NNMT inhibitor across independent cancer and reproductive-biology studies from 2023 onward ^[2][3][4][1].

In metabolic and cancer research, JBSNF-000088 is regarded as a useful, target-validated NNMT inhibitor tool compound. Outside that literature it is frequently and incorrectly described as a CNS or monoamine agent; the peer-reviewed record clearly identifies it as an NNMT inhibitor with metabolic and oncologic activity ^[1][2]. It has no legitimate standing as a human therapeutic or nootropic.